The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMonks Inv Regulatory News (MNKS)

Share Price Information for Monks Inv (MNKS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,160.00
Bid: 0.00
Ask: 1,486.00
Change: 0.00 (0.00%)
Spread: 328.00 (28.325%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,160.00
MNKS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

14 Jul 2020 17:03

RNS Number : 0004T
Monks Investment Trust PLC
14 July 2020
 

The Monks Investment Trust PLC

 

Legal Entity Identifier: 213800MRI1JTUKG5AF64

Regulated Information Classification: Annual Financial and Audit Reports

 

Annual Report and Financial Statements

 

Further to the preliminary statement of audited annual results announced to the Stock Exchange on 17 June 2020, The Monks Investment Trust PLC ("the Company") announces that the Company's Annual Report and Financial Statements for the year ended 30 April 2020, including the Notice of Annual General Meeting, has today been posted to shareholders and submitted electronically to the National Storage Mechanism where it will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism 

It is also available on the Company page of the Baillie Gifford website at: www.monksinvestmenttrust.co.uk (as is the preliminary statement of audited annual results announced by the Company on 17 June 2020).

 

Covid-19 coronavirus - Important note regarding arrangements for the Annual General Meeting (AGM)

The Board of The Monks Investment Trust PLC (Monks) recognises the public health risk associated with the Covid-19 outbreak arising from public gatherings and notes the Government's measures regarding such gatherings, travel and attendance at workplaces.

At the same time, the Board is conscious of the legal requirement for Monks to hold its AGM before the end of October. Given the current uncertainty around when public health concerns will have abated, the Board has for the time being decided to aim to follow the Company's customary corporate timetable and, accordingly, the Company's AGM is being convened to take place at 11am on Tuesday 1 September 2020 at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED. The Board will, however, continue to monitor developments and any changes will be advised to shareholders by post and details will be updated on the Company's website. In the meantime, the Board encourages all shareholders to submit proxy voting forms as soon as possible and, in any event, by no later than 11am on 27 August 2020.

We would encourage shareholders to monitor the Company's website at www.monksinvestmenttrust.co.uk. Should shareholders have questions for the Board or the Managers or any queries as to how to vote, they are welcome as always to submit them by email to trustenquiries@bailliegifford.com or call 0800 917 2112. Baillie Gifford may record your call.

 

Responsibility Statement of the Directors in respect of the Annual Financial Report

The Directors confirm that, to the best of their knowledge:

¾ the Financial Statements set out in the Annual Report and Financial Statements, which have been prepared in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', give a true and fair view of the assets, liabilities, financial position and net return of the Company;

¾ the Annual Report and Financial Statements taken as a whole is fair, balanced and understandable and provides the information necessary for shareholders to assess the Company's performance, business model and strategy; and

¾ the Strategic Report set out in the Annual Report and Financial Statements includes a fair review of the development and performance of the business and the position of the Company, together with a description of the principal risks and uncertainties that it faces (as also set out below).

 

Principal Risks relating to the Company

 

As explained on pages 27 and 28 of the Annual Report and Financial Statements, there is an ongoing process for identifying, evaluating and managing the risks faced by the Company on a regular basis. The Directors have carried out a robust assessment of the principal and emerging risks facing the Company, including those that would threaten its business model, future performance, solvency or liquidity. A description of these risks and how they are being managed or mitigated is set out below.

The Board considers the coronavirus (Covid-19) pandemic and Brexit to be factors which exacerbate existing risks, rather than new emerging risks. Their impact is considered within the relevant risks.

 

Financial Risk - the Company's assets consist mainly of listed securities and its principal and emerging financial risks are therefore market related and include market risk (comprising currency risk, interest rate risk and other price risk), liquidity risk and credit risk. An explanation of those risks and how they are managed is contained in note 19 to the Financial Statements on pages 52 to 55 of the Annual Report and Financial Statements. The Board has, in particular, considered the impact of heightened market volatility since the coronavirus (Covid-19) outbreak. To mitigate this risk, the composition and diversification of the portfolio by geography, industry, growth category, holding size and thematic risk category are considered at each Board meeting along with sales and purchases of investments. Individual investments are discussed with the investment managers together with their general views on the various investment markets and sectors. A strategy meeting is held annually. The Board has considered the potential impact on sterling from the remaining Brexit related uncertainties. The value of the Company's investment portfolio would be affected by any impact, positively or negatively, on sterling but such impact would be partially offset by the effect of exchange movements on the Company's US$ denominated borrowings.

 

Investment Strategy Risk - pursuing an investment strategy to fulfil the Company's objective which the market perceives to be unattractive or inappropriate, or the ineffective implementation of an attractive or appropriate strategy, may lead to reduced returns for shareholders and, as a result, a decreased demand for the Company's shares. This may lead to the Company's shares trading at a widening discount to their Net Asset Value. To mitigate this risk, the Board regularly reviews and monitors: the Company's objective and investment policy and strategy; the investment portfolio and its performance: the level of discount/premium to Net Asset Value at which the shares trade; and movements in the share register, and raises any matters of concern with the Managers.

 

Regulatory Risk - failure to comply with applicable legal and regulatory requirements such as the tax rules for investment trust companies, the UKLA Listing Rules and the Companies Act could lead to the Company being subject to tax on capital gains, suspension of the Company's Stock Exchange listing, financial penalties or a qualified audit report. To mitigate this risk, Baillie Gifford's Business Risk, Internal Audit and Compliance Departments provide regular reports to the Audit Committee on Baillie Gifford's monitoring programmes. Major regulatory change could impose disproportionate compliance burdens on the Company. In such circumstances representation is made to ensure that the special circumstances of investment trusts are recognised. Shareholder documents and announcements, including the Company's published Interim and Annual Report and Financial Statements, are subject to stringent review processes and procedures are in place to ensure adherence to the Transparency Directive and the Market Abuse Directive with reference to inside information.

 

Custody and Depositary Risk - safe custody of the Company's assets may be compromised through control failures by the Depositary, including breaches of cyber security. To mitigate this risk, the Board receives six-monthly reports from the Depositary confirming safe custody of the Company's assets held by the Custodian. Cash and portfolio holdings are independently reconciled to the Custodian's records by the Managers. The Custodian's audited internal controls reports are reviewed by Baillie Gifford's Business Risk Department and a summary of the key points is reported to the Audit Committee and any concerns investigated.

 

Operational Risk - failure of Baillie Gifford's systems or those of other third party service providers could lead to an inability to provide accurate reporting and monitoring or a misappropriation of assets. To mitigate this risk, Baillie Gifford has a comprehensive business continuity plan which facilitates continued operation of the business in the event of a service disruption (including any disruption resulting from the coronavirus outbreak) or major disaster. Since the introduction of the Covid-19 restrictions, almost all Baillie Gifford staff have been working from home and operations have continued very largely as normal. The Board reviews Baillie Gifford's Report on Internal Controls and the reports by other third party providers are reviewed by Baillie Gifford on behalf of the Board. The other key third party service providers have not experienced significant operational difficulties affecting their respective services to the Company.

 

Discount Risk - the discount at which the Company's shares trade relative to its Net Asset Value can change. The risk of a widening discount is that it may undermine investor confidence in the Company. To manage this risk, the Board monitors the level of discount/premium at which the shares trade and the Company has authority to buy back its existing shares when deemed by the Board to be in the best interests of the Company and its shareholders.

 

Political Risk - political change in areas in which the Company invests or may invest may increasingly have practical

consequences for the Company. To mitigate this risk, developments are closely monitored and considered by the Board. Following the departure of the UK from the European Union on 31 January 2020, the Board continues to assess the potential consequences for the Company's future activities. Whilst there remains considerable uncertainty, the Board believes that the Company's global portfolio, with only 7.3% of the portfolio exposed to the United Kingdom, positions the Company to be suitably insulated from Brexit-related risk.

 

Leverage Risk - the Company may borrow money for investment purposes. If the investments fall in value, any borrowings will magnify the extent of this loss. If borrowing facilities are not renewed, the Company may have to sell investments to repay borrowings. The Company can also make use of derivative contracts. To mitigate this risk, all borrowings require the prior approval of the Board and leverage levels are discussed by the Board and investment managers at every meeting. Covenant levels are monitored regularly. The majority of the Company's investments are in quoted securities that are readily realisable. Further information on leverage can be found on page 60 of the Annual Report and Financial Statements.

 

 

 

Baillie Gifford & Co Limited

Company Secretaries

14 July 2020

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSGPUGUMUPUGQC
Date   Source Headline
3rd May 202412:43 pmRNSNet Asset Value(s)
2nd May 202411:05 amRNSNet Asset Value(s)
1st May 20243:50 pmRNSClosed Period Confirmation
1st May 20243:45 pmRNSTotal Voting Rights
1st May 20243:39 pmRNSNet Asset Value(s)
30th Apr 20245:04 pmRNSTransaction in Own Shares
30th Apr 202412:01 pmRNSNet Asset Value(s)
30th Apr 20249:26 amRNSDirector/PDMR Shareholding
29th Apr 20244:57 pmRNSTransaction in Own Shares
29th Apr 20241:39 pmRNSNet Asset Value(s)
26th Apr 20245:13 pmRNSTransaction in Own Shares
26th Apr 202411:47 amRNSNet Asset Value(s)
25th Apr 20244:45 pmRNSDirector/PDMR Shareholding
25th Apr 202411:48 amRNSNet Asset Value(s)
24th Apr 20244:58 pmRNSTransaction in Own Shares
24th Apr 20241:08 pmRNSNet Asset Value(s)
23rd Apr 202411:56 amRNSNet Asset Value(s)
22nd Apr 202412:14 pmRNSNet Asset Value(s)
19th Apr 20245:07 pmRNSTransaction in Own Shares
19th Apr 202412:53 pmRNSNet Asset Value(s)
18th Apr 20244:55 pmRNSTransaction in Own Shares
18th Apr 202411:40 amRNSNet Asset Value(s)
17th Apr 20244:57 pmRNSTransaction in Own Shares
17th Apr 202412:58 pmRNSNet Asset Value(s)
16th Apr 20244:02 pmRNSNet Asset Value(s)
15th Apr 202411:29 amRNSNet Asset Value(s)
12th Apr 202412:05 pmRNSNet Asset Value(s)
11th Apr 20245:02 pmRNSTransaction in Own Shares
11th Apr 202411:56 amRNSNet Asset Value(s)
10th Apr 202412:47 pmRNSNet Asset Value(s)
9th Apr 20244:59 pmRNSTransaction in Own Shares
9th Apr 202411:28 amRNSNet Asset Value(s)
8th Apr 202411:35 amRNSNet Asset Value(s)
5th Apr 202411:38 amRNSNet Asset Value(s)
4th Apr 202411:38 amRNSNet Asset Value(s)
3rd Apr 202411:23 amRNSNet Asset Value(s)
2nd Apr 20244:34 pmRNSNet Asset Value(s)
2nd Apr 20244:02 pmRNSNet Asset Value(s)
2nd Apr 20242:28 pmRNSTotal Voting Rights
2nd Apr 20241:44 pmRNSNet Asset Value(s)
28th Mar 20244:53 pmRNSTransaction in Own Shares
28th Mar 202412:31 pmRNSNet Asset Value(s)
27th Mar 202412:05 pmRNSNet Asset Value(s)
26th Mar 20244:53 pmRNSTransaction in Own Shares
26th Mar 202412:07 pmRNSNet Asset Value(s)
25th Mar 202412:32 pmRNSNet Asset Value(s)
22nd Mar 20244:52 pmRNSTransaction in Own Shares
22nd Mar 202412:09 pmRNSNet Asset Value(s)
21st Mar 202412:06 pmRNSNet Asset Value(s)
20th Mar 20245:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.